MND-SMART trial update

picture of male participant talking to MND-SMART trial research nurse

April 2022: An independent review committe has completed the stage 1 analysis of memantine and trazodone and concluded that both drugs should continue in the MND-SMART trial.

An independent trial committee recently reviewed stage 1 data for the drugs we are currently testing in MND-SMART.

The outcome was that we should continue testing both memantine and trazodone, collecting data to determine whether either drug slows down the progression of MND.

In this video we provide an update on the outcomes and what this means for our trial participants.

This article was published on: Tuesday, April 05, 2022